Monitoring the effects of encorafenib and binimetinib in melanoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the relationship between plasma levels of encorafenib and binimetinib and the occurrence of dose-limiting toxicities in adult patients with BRAFV600-mutant metastatic melanoma. Participants will be those receiving these targeted therapies, either in combination or alone, during their treatment. The study will take place across five dermatology departments in Paris, where patients will be monitored for adverse effects and treatment efficacy over the first three months. The findings could provide valuable insights into optimizing treatment regimens for better patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adults ≥ 18 years of age

* Histologically confirmed advanced melanoma, stage III/stage IV inoperable (primary cutaneous, mucosal or unknown)
* Treatment with encorafenib and/or binimetinib, whatever the line of treatment, for curative purposes.
* Affiliated to a social security scheme or beneficiary of such a scheme
* informed and non-opposition collected.

Exclusion Criteria:

\-

Where it's running

• Department of Oncology-Dermatology, Ambroise Paré Hospital - APHP
  Boulogne-Billancourt, France Recruiting

Study contacts

• Principal investigator: Elisa FUNCK-BRETANO, MD, PhD — Department of Oncology-Dermatology, Ambroise Paré Hospital - APHP
• Study coordinator: Elisa FUNCK-BRENTANO, MD, PhD
• Email: elisa.funck-brentano@aphp.fr
• Phone: + 33171167721

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing the safety and effectiveness of ENV-501 in patients with HER3-expressing solid tumors

  This study is testing a new treatment called ENV-501 to see if it is safe and effective for people with advanced solid tumors that express HER3, like melanoma, lung cancer, and breast cancer.

  Recruiting at 5 sites Phase 1/2 Hummingbird Bioscience · La Jolla, California and 6 other locations · NCT06956690

• Treatment for BRAF Mutant Melanoma with Brain Metastases

  This study tests a new combination treatment for people with BRAF-mutated melanoma that has spread to the brain to see if it helps them live longer without their cancer getting worse.

  Recruiting at 17 sites Phase 2 Grupo Español Multidisciplinar de Melanoma · A Coruña, A Coruña and 17 other locations · NCT06887088

• Assessing a test to predict treatment response in advanced melanoma patients

  This study tests if the IOpener® melanoma test can help predict how well treatment will work for people with advanced melanoma who are starting their first-line therapy.

  Recruiting at 3 sites Pamgene International B.V. · Tübingen, Baden-Wurttemberg and 2 other locations · NCT06784778

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Skipping full lymph node removal for stage III melanoma patients who show a strong response in the index node

  This trial will see if patients with resectable stage III melanoma who get neoadjuvant ipilimumab plus nivolumab and show a major pathological response in the index lymph node can safely avoid therapeutic lymph node dissection.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06754904

• Evaluating the DermaSensor device for detecting melanoma

  This study is testing a new device to see if it can accurately detect skin lesions that might be melanoma in people aged 40 and older.

  Recruiting at 2 sites DermaSensor, Inc. · New Smyrna Beach, Florida and 1 other locations · NCT06666790

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.